Story

DaVita Shares Climb Over 10% on Stronger 2026 Profit Guidance

ENTHMSVIIDZHZH-TWJAKOHI
Sep 17, 20261 min read
DaVita Shares Climb Over 10% on Stronger 2026 Profit Guidance
Text size
Background

Shares of DaVita Inc. (NYSE:DVA) have rallied more than 10% this month after the kidney dialysis provider issued an optimistic full-year 2026 profit forecast that exceeded Wall Street estimates.

Upgraded Outlook

DaVita announced full-year 2026 earnings guidance in a range of $14.10 to $15.20 per share. The midpoint of this forecast is above the analyst consensus estimate of $14.57 per share, signaling stronger-than-expected profitability.

Following the announcement, the stock jumped 4.28% on September 14 to close at $189.32. According to Investing.com, shares have held those gains and were last trading at $193.86, representing a 10.06% increase since the beginning of September.

Wall Street View

Sample IUX Markets – In-articleAd

The upgraded guidance places DaVita's stock at a forward price-to-earnings multiple of roughly 12.9 times based on the midpoint of the forecast. Analyst consensus reflects a "Moderate Buy" rating on the stock, with an average price target of $233.43. This target implies a potential upside of approximately 23% from current trading levels.

DaVita's market capitalization now stands at $12.41 billion. The stock has traded within a 52-week range of $101.00 to $247.49.

Sector Context

DaVita's positive performance contrasts with the broader healthcare market, which has lagged in September. The S&P 500 Health Care index has declined 2.40% during the same period, highlighting DaVita as a notable outperformer within its sector.

Read next

More on Stocks
Back to latest news

LATEST